Double-blind Comparative Study of SYR-472

Trial Profile

Double-blind Comparative Study of SYR-472

Phase of Trial: Phase III

Latest Information Update: 23 May 2016

At a glance

  • Drugs Trelagliptin (Primary) ; Alogliptin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 26 Mar 2015 According to Takeda Pharmaceuticals media release, based on the results of this and other phase III trials ( see profile 226639 and 206116), Japanese Ministry of Health, Labour and Welfare has approved the New Drug Application of Zafatek (trelagliptin succinate).
    • 19 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top